Theragenics reunites with Oncura in brachytherapy pact
This article was originally published in Clinica
Brachytherapy specialist Theragenics has signed an exclusive agreement to provide Oncura with its TheraSeed palladium-103 seeds in the US and Canada. The deal will last until 31 May 2013 and has the option for additional one-year terms upon mutual agreement. Oncura will market TheraSeed, a therapy for prostate cancer, alongside its own products, the iodine-125-based OncoSeed and the RAPID Strand absorbable braided suture. The two firms previously had a similar agreement which ran from 2000-2005. When this contract finished, Buford, Georgia-based Theragenics said Oncura no longer shared its strategic objectives (www.clinica.co.uk, 17 December 2004). Since then, Oncura has become a subsidiary of GE Healthcare.
You may also be interested in...
Alere’s professional diagnostics business helped the firm record overall revenue growth in the fourth quarter of 2010, offsetting a fall in influenza-based sales in North America.
Integra LifeSciences has gained exclusive worldwide rights from Stout Medical to develop and commercialise an expandable interbody fusion device.
Gen-Probe recently launched its Panther automated molecular diagnostics system in Europe with the aim of bringing another dimension to its product portfolio. Joseph Harvey met the firm’s CEO, Carl Hull, at the launch of the product in Frankfurt to find how high the firm has set its sights in the molecular diagnostics sector and how it is going to achieve its goals